3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
1086
Neoplasms, Plasma Cell
255
Lymphoma
157
Lymphoma, Non-Hodgkin
150
Hodgkin Disease
135
Recurrence
130
Leukemia, Lymphocytic, Chronic, B-Cell
130
Precursor Cell Lymphoblastic Leukemia-Lymphoma
116
Myelodysplastic Syndromes
111
Leukemia
109
Leukemia, Myeloid, Acute
106
Lymphoma, Follicular
84
Lymphoma, Mantle-Cell
83
Lymphoma, B-Cell, Marginal Zone
82
Burkitt Lymphoma
76
Lymphoma, Large B-Cell, Diffuse
74
Myeloproliferative Disorders
70
Immunoglobulin Light-chain Amyloidosis
67
Lymphoma, Large-Cell, Immunoblastic
65
Hematologic Neoplasms
63
Primary Myelofibrosis
58
Leukemia, Myeloid, Chronic-Phase
57
Leukemia, Myeloid, Accelerated Phase
51
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
49
Waldenstrom Macroglobulinemia
46
Blast Crisis
44
Congenital Abnormalities
43
Leukemia, Myelomonocytic, Chronic
42
Dendritic Cell Sarcoma, Interdigitating
42
Smoldering Multiple Myeloma
41
Interventions
ogalvibart
1
crexavibart
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Purpura, Thrombotic Thrombocytopenic
×
Plasma cell
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn